



We couldn’t agree more with Dr. Ehrlich’s final com-
ment that suggests we eliminate this unnecessary banter about
the fibromyalgia label and “worry about the pains.” In fact, we
also agree that those patients meeting American College of
Rheumatology classification criteria for fibromyalgia (1) may
not have a discrete disease but are at the extreme end of a
continuum of patients with chronic musculoskeletal pain. Our
concern is that most who advocate abandoning the fibromyal-
gia construct also would like to abandon this group of patients.
We would reiterate that regardless of whether a label is
attached to these individuals, research into the physiology of
chronic musculoskeletal pain is a critically important endeavor
in the field of rheumatology.
As with many critics of the fibromyalgia construct, Dr.
Ehrlich veils his discomfort regarding patients with the fibro-
myalgia symptom complex by posing a legitimate concern
surrounding societal or legal issues. In this case the issue raised
is that assigning labels such as fibromyalgia may have an
adverse impact on patient outcome. Unfortunately, there are
few data that directly address whether this is the case or not. In
direct opposition to Dr. Ehrlich’s view, recent data reported by
White et al show that assigning a label of fibromyalgia to
individuals with chronic widespread pain has no meaningful
adverse affect on clinical outcome over the long term (2).
There are also data, however, suggesting that any disease label
may have a detrimental impact on patient behavior. In a study
of workers in an occupational setting, Haynes et al demon-
strated more than two decades ago that detecting and labeling
even an asymptomatic disease (hypertension) markedly in-
creased absenteeism from work (3).
Dr. Ehrlich seems to suggest that labels may be more
harmful in cases in which the etiology of the symptoms
reported by the patient has yet to be clearly understood. Stated
another way, he proposes that syndromes characterized by
subjective symptoms should not be given a label that implies
those who have the symptoms are abnormal, perhaps in
contradistinction to syndromes characterized by alterations of
easily measured variables. It is not clear to us why this should
be the case, unless one questions the veracity of self-reported
symptoms. Furthermore, even when a variable is objective, the
definition of what constitutes abnormal may change over time
(e.g., hypertension, hypercholesterolemia, obesity) as new re-
search changes our understanding of human physiology.
The implications of Dr. Ehrlich’s proposition to elim-
inate semantic terms from our clinical vernacular would be
enormous. As he himself notes, the symptoms do not go away;
the label only changes. If we discard the fibromyalgia label,
then we should logically reject other labels such as migraine
headache, dyslexia, all psychiatric disorders, etc. This would
require a tremendous paradigm shift in how we practice
clinical medicine, since the aggregate data suggest that approx-
imately half of the visits to primary care physicians are for
symptoms and syndromes that fall into the category of not
being easily measurable in a purely objective manner (4).
Labels are like any intervention, and can lead to both
positive and negative effects. The potential positive effects of
labels include eliminating unnecessary diagnostic testing, alle-
viating concerns about life-threatening illnesses, and providing
an improved understanding of the most appropriate course of
management by both physicians and patients. As with any
intervention, we should use a label only when our judgment is
that the likelihood of benefit outweighs possible negative
effects.
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Pyridostigmine for fibromyalgia: comment on the
article by Paiva and a historical vignette
To the Editor:
Rob Bennett’s group is to be congratulated, as usual,
for an important extension of their ongoing outstanding work
investigating the role of growth hormone in fibromyalgia (1).
Their recently published insight that pyridostigmine reverses
the impaired growth hormone response to exercise suggests a
possible therapeutic role for this agent, one that was first
propounded 50 years ago.
Long before there were rheumatologists, neurologists
managed a group of patients with “neurasthenia and myas-
thenic states.” Dr. J.E. Tether headed the myasthenia gravis
clinic at Indiana University School of Medicine for more than
30 years. In 1961, a textbook on myasthenia gravis included a
chapter he wrote entitled, “Mild myasthenic state” (2). Of the
2,327 patients he followed, 775 were diagnosed with mild
myasthenic state, in that they had clinical symptoms but a
negative tensilon test. The patients were almost all women who
were diagnosed between the ages of 20 and 40. The onset of
symptoms was usually gradual, but sometimes occurred after a
traumatic event and was exacerbated by exertion, infection,
menstruation, and emotion. The principal clinical features of
this group included fatigue, tightness or stiffness and aching in
the back of the neck, chest heaviness, aching in the interscap-
ular and lumbar areas, and “sad, tired expressions.” Dr. Tether
noted that these patients also responded to pyridostigmine,
and could not explain why they “flared” when the medication
was withdrawn. Similar studies from myasthenia clinics at
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